• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Vaccine Adverse Events / Vaccine Associated Disorders / Autism / Neuroprotection in the Newborn Infant

Neuroprotection in the Newborn Infant

February 23, 2011 By Jonathan Leave a Comment

NIH
Pub Med Central

Clin Perinatol. Author manuscript; available in PMC 2010 December 1.
Published in final edited form as:
Clin Perinatol. 2009 December; 36(4): 859–880.

doi: 10.1016/j.clp.2009.07.013.

Fernando F. Gonzalez, M.D.a and Donna M. Ferriero, M.D.ab

Synopsis

Neonatal brain injury is an important cause of death and disability, with pathways of oxidant stress, inflammation, and excitotoxicity that lead to damage that progresses over a long period of time. Therapies have classically targeted individual pathways during early phases of injury, but more recent therapies such as growth factors may also enhance cell proliferation, differentiation and migration over time. More recent evidence suggests combined therapy may optimize repair, decreasing cell injury while increasing newly born cells.

Causes of early brain injury include stroke, birth trauma, metabolic or genetic disorders, status epilepticus, and asphyxial events. Perinatal asphyxia presents as encephalopathy, or hypoxic ischemic encephalopathy, occurring in 3 to 5 in 1000 live births [1], while stroke studies conservatively estimate an incidence of 1 in 4000 live births [2]. It is classically thought that hypoxic-ischemic (HI) injury leads to periventricular white matter damage in premature infants, while term infants develop cortical/subcortical lesions [3], but more recent evidence suggests that this distinction in injury type may not be so clear [4]. While many suffering from perinatal brain injury die during early life, the majority of survivors exhibit neurological deficits that persist, such as cerebral palsy, mental retardation or epilepsy [5]. Aside from hypothermia, no established therapies exist, and treatment and care for the sequelae of early brain injury requires significant resources. Even after maximal care, there is often little improvement in an individual’s overall abilities, with long-term effects on the family, health care system, and society [6].

Read Full Article…

Clin Perinatol. Author manuscript; available in PMC 2010 December 1.
Published in final edited form as:
Clin Perinatol. 2009 December; 36(4): 859–880.

doi: 10.1016/j.clp.2009.07.013.

PMCID: PMC2786822
NIHMSID: NIHMS137355
Copyright notice and Disclaimer
Neuroprotection in the Newborn Infant
Fernando F. Gonzalez, M.D.a and Donna M. Ferriero, M.D.ab
a Department of Pediatrics; University of California, San Francisco (FFG, DMF)
b Department of Neurology; University of California, San Francisco (DMF)
Author contact information: Donna M. Ferriero, M.D. Neonatal Brain Disorders Laboratory University of California, San Francisco 521 Parnassus Ave. C215 Box 0663 San Francisco, CA 94143 Phone: (415) 502-5820 Fax: (415) 502-5821 ; Email: ferrierod@neuropeds.ucsf.edu
Fernando F. Gonzalez, M.D. Neonatal Brain Disorders Laboratory University of California, San Francisco 521 Parnassus Ave. C215 Box 0663 San Francisco, CA 94143 Phone: (415) 502-8932 Fax: (415) 514-0235 gonzalezf@peds.ucsf.edu
The publisher’s final edited version of this article is available at Clin Perinatol
Publisher’s Disclaimer
Synopsis
Neonatal brain injury is an important cause of death and disability, with pathways of oxidant stress, inflammation, and excitotoxicity that lead to damage that progresses over a long period of time. Therapies have classically targeted individual pathways during early phases of injury, but more recent therapies such as growth factors may also enhance cell proliferation, differentiation and migration over time. More recent evidence suggests combined therapy may optimize repair, decreasing cell injury while increasing newly born cells.
Keywords: neonatal stroke, hypoxia, ischemia, neuroprotection, neurogenesis
  • Other Sections▼
    • Synopsis
    • HYPOTHERMIA
    • GROWTH FACTORS
    • STEM CELL THERAPY
    • ANTIOXIDANTS
    • EXCITOTOXICITY
    • ANTI-INFLAMMATORY THERAPY
    • CELL DEATH INHIBITORS
    • COMBINATION THERAPY
    • CONCLUSION
    • References
Causes of early brain injury include stroke, birth trauma, metabolic or genetic disorders, status epilepticus, and asphyxial events. Perinatal asphyxia presents as encephalopathy, or hypoxic ischemic encephalopathy, occurring in 3 to 5 in 1000 live births [1], while stroke studies conservatively estimate an incidence of 1 in 4000 live births [2]. It is classically thought that hypoxic-ischemic (HI) injury leads to periventricular white matter damage in premature infants, while term infants develop cortical/subcortical lesions [3], but more recent evidence suggests that this distinction in injury type may not be so clear [4]. While many suffering from perinatal brain injury die during early life, the majority of survivors exhibit neurological deficits that persist, such as cerebral palsy, mental retardation or epilepsy [5]. Aside from hypothermia, no established therapies exist, and treatment and care for the sequelae of early brain injury requires significant resources. Even after maximal care, there is often little improvement in an individual’s overall abilities, with long-term effects on the family, health care system, and society [6].
A search for therapies that can prevent injury progression or enhance repair of the immature brain continues, with the goal of improving long-term motor and cognitive outcomes. Because the neonatal and adult brain do not respond to insults in the same manner, secondary to differences in gene regulation during hypoxia and altered susceptibility to oxidative stress and excitotoxicity, alternate therapies must be sought [7]. Damage occurs via multiple pathways, and repair occurs over a period of days to weeks, if not months [8]. While some therapies that manipulate injury pathways show promise, not all neonates will benefit from treatment. Damage may be so severe or prolonged that repair may not be possible, or survivors may be particularly devastated [9].

Related

Filed Under: Autism, Febrile Seizures, Hepatitis B, InflammatoryBowel Disease, MMR, Nervous System, Shaken Baby Syndrome, Vaccine Adverse Events, Vaccine Science Tagged With: Andrew Wakefield, autism, cervarix, immunizations, pharmaceuticals, Vaccine Adverse Reactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Post-Cervarix Syndrome: Deanna from Margate, Kent, UK

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

map Ireland

TV3 Ireland: HPV Vaccine Documentary

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2025 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in